Category
162 articles — page 7 of 14
Vitiligo changes slowly — slowly enough that without consistent documentation you cannot tell whether treatment is working. Here is a practical system for tracking patches, understanding clinical scoring tools, and setting realistic timelines.
Vitiligo is not a painful condition in the conventional sense — but depigmented skin does create situations where pain can occur. Here is the clear answer and the specific circumstances where discomfort arises.
Vitiligo that begins after the age of 40 has a distinct profile — different triggers, different comorbidity associations, and a different prognosis trajectory compared to early-onset disease. Here is what the evidence shows.
Leukotrichia — white hair within vitiligo patches — is more than a cosmetic feature. It indicates deeper follicular melanocyte loss and significantly affects repigmentation prognosis. Here is what it means and why it matters.
Surgical melanocyte transplantation is the most effective option for stable vitiligo that has not responded to medical treatment — particularly in areas with depleted follicular reserves. Here is how it works, who qualifies, and what outcomes look like.
Minocycline is a tetracycline antibiotic used off-label for vitiligo because of its anti-inflammatory and immunomodulatory properties — not its antibiotic effect. The evidence is limited but the rationale is plausible. Here is the honest picture.
Narrowband UVB and excimer laser both emit 308nm therapeutic UV but deliver it very differently. Choosing between them depends on how much of your body is affected, your access to equipment, and your budget. Here is the head-to-head comparison.
The three main topical approaches to vitiligo — JAK inhibitor (Opzelura), calcineurin inhibitor (tacrolimus), and corticosteroids — each have different mechanisms, evidence levels, side effects, and appropriate uses. Here is the complete comparison.
Polypodium leucotomos is an oral fern extract with antioxidant and photoprotective properties. The evidence base for its use as a phototherapy adjunct in vitiligo is modest but real — here is what the trials actually show.
Pseudocatalase cream (PC-KUS) is frequently asked about in vitiligo communities. The evidence is weak, the mechanism is contested, and the product is not widely available. Here is the honest assessment.
PUVA — psoralen plus UVA — was the standard phototherapy for vitiligo for decades before narrowband UVB became dominant. It still has a role in specific situations. Here is how it works and how it compares to NbUVB.
Swimming raises specific questions for vitiligo patients — sun protection that survives water, chlorine effects on patches, Koebner risk, and waterproof camouflage options. Here is the practical guide.
